Gynecologic Oncology · MRI · FIGO 2023

Uterine High-Grade Malignancy MRI Builder

MRI characterization, local staging, metastatic assessment, differential diagnosis and structured reporting for uterine carcinosarcoma and high-grade endometrial carcinoma.

Suspected tumor category

Not yet assessed

Local extent

Not yet assessed

Metastatic disease

Not yet assessed

Report completion12%

MRI findings may suggest an aggressive uterine histology, but carcinosarcoma cannot be reliably distinguished from high-grade endometrial carcinoma by imaging alone. Final histologic classification requires tissue diagnosis.

Use de-identified clinical information only. Do not enter protected health information.

Overview & clinical context

Mode, histology and indication

Mode

Known or suspected histology

Clinical indication

Comparison

Still to complete: Known or suspected histology, Tumor epicenter / location, Myometrial invasion category, Cervical stromal status, Serosal status, Adnexal status, Vaginal / parametrial status, Pelvic and para-aortic nodal status, Bladder / bowel mucosal status, Distant metastatic status, Tumor dimensions, T2 characteristics, Diffusion, Enhancement, Examination quality.

Step 1 of 9 · Clinical context

Live report preview

—

Report style

Additional findings

EXAM
MRI pelvis without and with IV contrast.

COMPARISON
None.

TECHNIQUE
MRI pelvis without and with IV contrast.

FINDINGS

Peritoneum
No pelvic peritoneal implants are identified. No extrapelvic peritoneal implants are identified within the field of view.

Distant Disease
No distant metastatic disease is identified within the field of view. The lungs are not fully assessed on this examination. Dedicated chest imaging is recommended for complete staging of an aggressive uterine malignancy.

Additional Findings
No definite cervical stromal invasion. No uterine serosal breach. No parametrial or vaginal extension. No definite bladder or rectal mucosal invasion. No suspicious adnexal mass. No suspicious pelvic or para-aortic adenopathy. No pelvic or extrapelvic peritoneal implants. No ascites. No distant metastatic disease within the field of view.

IMPRESSION
1. MRI cannot assess lymphovascular space invasion, nodal micrometastases or molecular subtype; the final FIGO 2023 stage requires integration with pathology and molecular classification. Dedicated chest CT is recommended for complete staging.